ManishaBhutaniMD

Oncology • Charlotte, NC

Hematologic Oncology

Physician

Join to view full profile

Dr. Bhutani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhutani's full profile

Already have an account?

Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204
Phone+1 980-442-2000

Fax+1 704-355-5800

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Sparrow Hospital/Michigan State UniversityResidency, Internal Medicine, 2008 - 2011
Pt. B.D. Sharma Postgrad Institute of Medical ScienceClass of 1990

Certifications & Licensure

NC State Medical License 2014 - 2025
MI State Medical License 2008 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff
Leukemia & Lymphoma. 2024-12-01
1 citations
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple My...
Hermann Einsele, Philippe Moreau, Nizar Bahlis, Manisha Bhutani, Laure Vincent
Advances in Therapy. 2024-04-01
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
Hamid Ehsan, Myra Robinson, Peter M Voorhees, Kristen Cassetta, Shanice Borden
Life. 2024-03-14

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

International Myeloma Foundation Medical Student Scholars for Health Equity in Myeloma Present Posters at the 2024 NMA Annual Convention & Scientific AssemblyAugust 15th, 2024
To Focus on Hematologic Malignancies in Upcoming State of the Science SummitApril 18th, 2018
® to Host State of the Science Summit™: Diagnosis, Management and Treatment of Multiple MyelomaMay 17th, 2017